Colon Cancer

P2, N=21, Completed, First Affiliated Hospital, Sun Yat-Sen University | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025

P=N/A, N=700, Active, not recruiting, Blokhin's Russian Cancer Research Center

The clinical course and histologic features, including a reproducible eruption upon re-exposure, were strongly consistent with a drug-induced type IV hypersensitivity reaction, supporting the diagnosis. This case underscores the importance of recognizing delayed cutaneous adverse reactions when considering treatment interruption and re-challenge during prolonged or intermittent cetuximab therapy.

P2, N=128, Not yet recruiting, Hebei Medical University Fourth Hospital

Our findings provide compelling evidence that rational genetic engineering of tumor cells can effectively transform the extracellular vesicles they produce, shifting their immunosuppressive, tumor-supporting potential into an immunogenic one. Interleukin-18-loaded and TGF-β1-deprived TEVs can serve as a highly versatile and naturally immunogenic platform for the next-generation DC-based anticancer vaccines.

In a separate multivariable model, elevated CEA was also independently associated with poorer overall survival.ConclusionCIPI independently predicts overall survival in patients with de novo metastatic colon cancer. Its simplicity, cost-effectiveness, and derivation from routine laboratory data make it a practical and promising tool for baseline risk stratification and individualized follow-up planning.

As a first-line treatment for patients with left-sided all RAS or KRAS wild-type mCRC, panitumumab plus doublet chemotherapy may be suggested better efficacy outcomes than cetuximab plus doublet chemotherapy.

In contrast, rs9940128 showed no significant association with CRC risk in any genetic model or stratum (all p > 0.05). The FTO rs9930506 polymorphism is associated with reduced CRC risk in this population, suggesting its role as a potential susceptibility marker.

P2, N=60, Not yet recruiting, Oncolytics Biotech

These insights provide a deeper understanding of the molecular mechanisms underlying CRC progression and highlight the potential of ZNF263 and GPSM2 as therapeutic targets for intervention. This study underscores the importance of early detection and exploration of targeted therapies to improve CRC patient outcomes.

Apigenin and kaempferol showed potential as dual-targeting agents for colon cancer therapy. Cell culture and animal model studies in future are warranted to substantiate the mechanistic roles in tumor suppression.

Rutin, trifolin (a kaempferol glycoside), and epigallocatechin exhibited the strongest binding (e.g. rutin: - 8.85 kcal/mol to VEGF-A), surpassing the reference inhibitor Pazopanib (- 3.56 kcal/mol) with multiple stabilizing interactions with these proteins, suggesting potential to interfere with tumor angiogenesis and cell survival pathways. Collectively, these findings provide a scientific basis for the traditional use of T. globiferus and support its fraction as promising sources of multi-targeted anticancer agents. The identification of bioactive compounds further establishes a foundation for bioassay-guided isolation, mechanistic validation, and future drug development.